Unlock instant, AI-driven research and patent intelligence for your innovation.

Transdermal delivery of drocannabinol

一种屈大麻酚、透皮递送的技术，应用在屈大麻酚的透皮递送领域，能够解决恶心和呕吐不方便、未提供具有任何药物效用组合物、精神症状增加等问题

Pending Publication Date: 2022-06-21
STARTON THERAPEUTICS INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This dosage regimen is not convenient for patients who are already experiencing nausea and vomiting
A second challenge is that pharmacological responses are dose-related and subject to interpatient variability
A third challenge is the increased likelihood of disturbing psychiatric symptoms at maximum doses
A fourth challenge is that after oral administration, dronabinol undergoes first-pass hepatic metabolism and is highly lipid soluble; therefore, 10%-20% of the administered dose reaches the systemic circulation
Therefore, the '992 publication does not provide a composition with any pharmaceutical utility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal delivery of drocannabinol
  • Transdermal delivery of drocannabinol
  • Transdermal delivery of drocannabinol

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Transdermal and / or topical formulations contain solvents, alone or in combination, including but not limited to alcohols C1-C20 such as, but not limited to (methanol, ethanol, isopropanol, butanol, propanol, etc.), polyols, diols Alcohols such as but not limited to (propylene glycol, polyethylene glycol, dipropylene glycol, hexylene glycol, butylene glycol, glycerol, etc.), glycol derivatives, pyrrolidones such as but not limited to (N methyl 2-pyrrolidone, 2-pyrrolidone, etc. ), sulfoxides such as but not limited to (dimethyl sulfoxide, decyl methyl sulfoxide, etc.), dimethyl isosorbide, mineral oil, vegetable oil, water, polar solvents, semi-polar solvents, non-polar solvents , Volatile chemicals such as but not limited to (ethanol, propanol, ethyl acetate, acetone, methanol, dichloromethane, chloroform, toluene, IPA), acids (such as but not limited to acetic acid, lactic acid) that can be used to prepare matrix patches , levulinic acid, fatty acid), alkali, etc. In ...

Embodiment 2

[0112] Transdermal and / or topical formulations contain, alone or in combination, gelling and / or thickening and / or suspending agents, including but not limited to natural polymers, polysaccharides and derivatives thereof such as, but not limited to (agar, Alginic acid and derivatives, cinnamon, collagen, gelatin, gellan gum, guar gum, pectin, potassium or sodium carrageenan, tragacanth, xanthan, copa, chitosan, resin, etc.), semi- Synthetic polymers and derivatives thereof such as (without any limitation) cellulose and derivatives thereof (methyl cellulose, ethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose etc.), synthetic polymers and derivatives thereof such as (without limitation) carboxyvinyl polymers or carbomers (Carbopol 940, Carbopol 934, Carbopol 971pNF), polyethylene and its copolymers, etc. , clays such as but not limited to (silicates, bentonites), silica, polyvinyl alcohol, acrylic polymers (acrylic resins), acrylates...

Embodiment 3

[0114] Transdermal and / or topical formulations of the present disclosure may contain, alone or in combination, penetration enhancers known to those skilled in the art, without any limitation, such as sulfoxides and similar chemicals such as, but not limited to ( dimethyl sulfoxide, dimethyl acetamide, dimethyl formamide, decyl methyl sulfoxide, dimethyl isosorbide, etc.), azone, pyrrolidone such as but not limited to (N-methyl-2-pyrrolidone , 2-pyrrolidone, etc.), esters, fatty acid esters such as but not limited to (propylene glycol monolaurate, butyl acetate, ethyl acetate, isopropyl myristate, isopropyl palmitate, methyl acetate, oleic acid capric, glycerol monooleate, glyceryl monolaurate, lauryl laurate, etc.), fatty acids such as but not limited to (capric, caprylic, lauric, oleic, myristic, linoleic, stearic , palmitic acid, etc.), alcohols, fatty alcohols and glycols such as but not limited to (oleyl alcohol, nathanol, dodecanol, propylene glycol, glycerol, etc.), ethe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A transdermal drug delivery system comprising drocannabinol is provided. The drocannabinol transdermal delivery system provides a drug plasma concentration at a predetermined rate over a predetermined period of time, thereby providing a simplified treatment regimen for the treatment and / or prevention of nausea and / or vomiting associated, for example, with chemotherapy by reducing the frequency of administration.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of US Provisional Patent Application No. 62 / 910,255, filed October 3, 2019, which is incorporated herein by reference. technical field [0003] The present disclosure relates to the treatment of nausea and vomiting, such as those commonly experienced by patients undergoing chemotherapy. Background technique [0004] Nausea and vomiting are common side effects of cancer chemotherapy. such as dronabinol and 5-HT are recommended 3 Drugs that are receptor antagonists are used to treat nausea and vomiting associated with cancer chemotherapy. Sometimes, one or more medications can be used to prevent nausea and vomiting (see Herrsted J., et al., 2016 Updated MASCC / ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic RiskChemotherapy. Support Care Cancer 2017 Jan;25(1):277-288. e-Edition Jul 22, 2016). [0005] Dronabinol is the synthetic form of delta-9...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K9/70
CPCA61K9/0021A61K9/0014A61K9/7023A61K9/703A61K31/352A61P3/04A61P1/08A61K9/7084
Inventor F.M.普拉科吉亚尼斯T.拉瑟N.莫迪M.博罗文斯卡亚
Owner STARTON THERAPEUTICS INC